Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch Biotech Moves Hepatitis B Vaccine For Huge China Market

This article was originally published in PharmAsia News

Executive Summary

Crucell, a biopharma company based in The Netherlands, has applied for registration and quality control of its hepatitis B vaccine in China where it believes the market to be $100 million. The Hepavax-Gene is the world's third-best selling vaccine for the disease, accounting for 600 million doses worth of sales in the past 12 years. In China, the Dutch biotech is aiming for the country's high-end sector dominated by young adults. One advantage in China is the vaccine contains no thiomersal, which already is being phased out for treatment of children in other countries. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067386

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel